Imricor Medical Systems (ASX:IMR) has achieved a major regulatory milestone with the US Food and Drug Administration granting 510(k) clearance for its NorthStar Mapping System.
The approval marks NorthStar as the first and only MRI-native 3D mapping and guidance system cleared for use in the United States, the world's largest electrophysiology market.
NorthStar is designed to serve as the "central hub" for interventional cardiac MRI labs, providing a software-centric platform that allows physicians to perform cardiac procedures under real-time MRI guidance.
Unlike traditional methods, this system enables a 100% radiation-free environment, leveraging superior soft-tissue imaging to improve the precision of minimally invasive treatments.
This clearance is the second FDA win for Imricor this month, following the approval of its Vision-MR Diagnostic Catheter.
Chair and CEO Steve Wedan noted that NorthStar represents the foundation of the company's "software era," with a platform capable of integrating future AI enhancements and expanding into a broad pipeline of MRI-guided procedures.